Silicon Image, Inc. (NASDAQ:SIMG) introduced the camerIC™-3D/64MP, the newest member of its camerIC family of camera processor IP cores capable of supporting 3D and up to 8Kx8K (64 megapixel) still images and video. camerIC-3D/64MP is optimized for integration into low-power video system-on-chip (SoC) application processors for mobile devices such as cell phones, tablets, netbooks, digital still cameras (DSCs) and camcorders as well as video surveillance systems.
Silicon Image, Inc. engages in the design, development, and implementation of semiconductors and intellectual property (IP) solutions for the storage, distribution, and presentation of high-definition content in home and mobile environments worldwide.
Power3 Medical Products, Inc. (PWRM.OB) tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
PWRM applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials.
* Alzheimer’s disease is among the most well known form of dementia, a broad term when it comes to forgetfulness and other intellectual abilities critical enough to obstruct everyday life.
* Cancer of the breast is a form of cancer in which cells in the breast split and also grow without usual control.
* Parkinson’s disease (PD) is associated with a team of disorders called motor system disorders, which are the result of the losing of dopamine-producing brain cells. Some fundamental symptoms of PD are generally tremor, or moving in hands, arms, legs, jaw, and face; hardness, or maybe tightness of the limbs and trunk; bradykinesia, or slowness of movement; and postural lack of stability, or reduced balance as well as co-ordination.
* Amyotrophic lateral sclerosis (abbreviated ALS, also referred to as Lou Gehrig’s disease) is a form of motor neuron disease. ALS is a progressive, fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement. The condition is often called Lou Gehrig’s disease in North America, after the famous New York Yankees baseball player who was diagnosed with the disease in 1939.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).
For more information about this company please visit http://www.power3medical.com
Sangamo Biosciences, Inc. (NASDAQ:SGMO) announced that Edward Lanphier, Sangamo’s president and CEO, will provide an update on the progress of Sangamo’s ZFP Therapeutic® development programs and an overview of the company’s business strategy at 2:30 pm ET on Monday, February 14, 2011 at the 13th Annual BIO CEO & Investor Conference which will be held in New York City. The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. For more information about Sangamo, visit the company’s website at http://www.sangamo.com/.
The widespread acceptance of vehicles incorporating hybrid technology has been the result of growing awareness among consumers, governments and car producers that this technology is here to stay and has to be accepted with open arms.
EVCARCO, Inc. (EVCA.OB) has retained The Eversull Group for Financial Public Relations, Investor Relations and Shareholder Services Consulting.
The Eversull Group, based in Frisco, Texas, a suburb of Dallas, has been in business since 1997 and over that time, has been very successful in getting national and international newspaper, magazine and television press coverage, financing, and individual and institutional investors for their clients, and has a good track record moving OTCBB companies to a primary stock exchange.
Note: Hybrid Cars market for global and the regional markets include North America, Japan, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 24 independent countries across North America – the United States and Canada; Europe – Top 8 countries consisting France, Germany, Italy, the Netherlands, Spain, Sweden, Switzerland, the United Kingdom and 6 key countries of Austria, Belgium, Greece, Ireland, Norway and Portugal in Rest of Europe; Asia-Pacific – Australia, China, India, South Korea, New Zealand, Singapore, Taiwan and Thailand.
The Market for Hybrid Electric cars is expected to register an impressive CAGR of 22.9% during 2006-2015 to reach 2.5 million units by 2015. (Source http://www.reportlinker.com/p0362926/Hybrid-Electric-Cars-A-Global-Marke... )
EVCARCO Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCA is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
For more information about this company please visit http://www.evcarco.com
ISTA Pharmaceuticals, Inc. (NASDAQ:ISTA) announced that it will release fourth quarter and full-year 2010 financial results after the market closes on February 23, 2011. In conjunction, the Company will host a conference call at 4:30 p.m. Eastern Time. Conference call can be access at: Internet: www.istavision.com To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the replay is 11293297. This conference call also will be webcast live and archived on ISTA’s website until March 23, 2011.
ISTA Pharmaceuticals, Inc., is the fourth largest and fastest growing branded prescription eye care business in the United States, with an expanding focus on allergy therapeutics. For additional information about ISTA Pharmaceuticals, please visit the corporate website at www.istavision.com.
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received fifteen thousand dollars in cash and thirty-five thousand EVCARCO, Inc. (EVCA.OB) restricted shares for 30 days (which has expired) of advertising services. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).